BPMX Craters, KPTI Surges On Deal With Anivive, PFE Seeks New Use For Old Drug

Shares of Biopharmx Corp. (BPMX) were down 29% in after-hours on Wednesday, despite its phase 2b clinical trial of BPX-011 for the treatment of moderate-to-severe acne meeting the primary endpoint.

from RTT - Biotech http://ift.tt/2pKjM75
via IFTTT